CHF1.08
5.99% today
SIX Swiss Exchange, Apr 01, 05:30 pm CET
ISIN
CH0363463438
Symbol
IDIA
Sector
Industry

Idorsia Stock price

CHF1.08
-0.16 12.83% 1M
-0.45 29.50% 6M
+0.26 31.39% YTD
-1.75 61.81% 1Y
-17.61 94.22% 3Y
-23.18 95.55% 5Y
-12.57 92.09% 10Y
SIX Swiss Exchange, Closing price Tue, Apr 01 2025
+0.06 5.99%
ISIN
CH0363463438
Symbol
IDIA
Sector
Industry

Key metrics

Market capitalization CHF227.97m
Enterprise Value CHF1.36b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.48
P/S ratio (TTM) P/S ratio 2.09
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -28.47%
Revenue (TTM) Revenue CHF109.01m
EBIT (operating result TTM) EBIT CHF-331.30m
Free Cash Flow (TTM) Free Cash Flow CHF-373.23m
Cash position CHF124.36m
EPS (TTM) EPS CHF-1.38
P/E forward negative
P/S forward 1.51
EV/Sales forward 9.00
Show more

Is Idorsia a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Idorsia Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Idorsia forecast:

1x Hold
50%
1x Sell
50%

Analyst Opinions

2 Analysts have issued a Idorsia forecast:

Hold
50%
Sell
50%

Financial data from Idorsia

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
109 109
28% 28%
100%
- Direct Costs 51 51
97% 97%
47%
58 58
54% 54%
53%
- Selling and Administrative Expenses 245 245
33% 33%
225%
- Research and Development Expense 126 126
56% 56%
116%
-314 -314
40% 40%
-288%
- Depreciation and Amortization 17 17
10% 10%
16%
EBIT (Operating Income) EBIT -331 -331
39% 39%
-304%
Net Profit -250 -250
16% 16%
-230%

In millions CHF.

Don't miss a Thing! We will send you all news about Idorsia directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO André Muller
Founded 2017
Website www.idorsia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today